Cargando…

Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby

Very long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive mitochondrial fatty acid oxidation disorder that manifests in three clinical forms: (a) severe, (b) milder, and (c) myopathic. Patients with the myopathic form present intermittent muscular symptoms such as myalgia,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kenji, Matsubara, Keiichi, Matsubara, Yuko, Watanabe, Asami, Kawakami, Sanae, Ochi, Fumihiro, Kuwabara, Kozue, Mushimoto, Yuichi, Kobayashi, Hironori, Hasegawa, Yuki, Fukuda, Seiji, Yamaguchi, Seiji, Taketani, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718132/
https://www.ncbi.nlm.nih.gov/pubmed/31497477
http://dx.doi.org/10.1002/jmd2.12061
_version_ 1783447688635744256
author Yamada, Kenji
Matsubara, Keiichi
Matsubara, Yuko
Watanabe, Asami
Kawakami, Sanae
Ochi, Fumihiro
Kuwabara, Kozue
Mushimoto, Yuichi
Kobayashi, Hironori
Hasegawa, Yuki
Fukuda, Seiji
Yamaguchi, Seiji
Taketani, Takeshi
author_facet Yamada, Kenji
Matsubara, Keiichi
Matsubara, Yuko
Watanabe, Asami
Kawakami, Sanae
Ochi, Fumihiro
Kuwabara, Kozue
Mushimoto, Yuichi
Kobayashi, Hironori
Hasegawa, Yuki
Fukuda, Seiji
Yamaguchi, Seiji
Taketani, Takeshi
author_sort Yamada, Kenji
collection PubMed
description Very long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive mitochondrial fatty acid oxidation disorder that manifests in three clinical forms: (a) severe, (b) milder, and (c) myopathic. Patients with the myopathic form present intermittent muscular symptoms such as myalgia, muscle weakness, and rhabdomyolysis during adolescence or adulthood. Here, the clinical symptoms and serum creatine kinase (CK) levels of a pregnant 31‐year‐old woman with the myopathic form of VLCAD deficiency were reduced during pregnancy. Clinical symptoms rarely appeared during pregnancy, although she had sometimes suffered from muscular symptoms before pregnancy. When ritodrine was administered for threatened premature labor at 35 weeks of gestation, her CK level was elevated to over 3900 IU/L. She delivered a full‐term baby via cesarean section but suffered from muscle weakness with elevated CK levels soon after delivery. It has been reported that an unaffected placenta and fetus can improve maternal β‐oxidation during pregnancy. However, in our case, the baby was also affected by VLCAD deficiency. These suggest that the clinical symptoms of a woman with VLCAD deficiency might be reduced during pregnancy even if the fetus is affected with VLCAD deficiency.
format Online
Article
Text
id pubmed-6718132
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-67181322019-09-06 Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby Yamada, Kenji Matsubara, Keiichi Matsubara, Yuko Watanabe, Asami Kawakami, Sanae Ochi, Fumihiro Kuwabara, Kozue Mushimoto, Yuichi Kobayashi, Hironori Hasegawa, Yuki Fukuda, Seiji Yamaguchi, Seiji Taketani, Takeshi JIMD Rep Case Reports Very long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive mitochondrial fatty acid oxidation disorder that manifests in three clinical forms: (a) severe, (b) milder, and (c) myopathic. Patients with the myopathic form present intermittent muscular symptoms such as myalgia, muscle weakness, and rhabdomyolysis during adolescence or adulthood. Here, the clinical symptoms and serum creatine kinase (CK) levels of a pregnant 31‐year‐old woman with the myopathic form of VLCAD deficiency were reduced during pregnancy. Clinical symptoms rarely appeared during pregnancy, although she had sometimes suffered from muscular symptoms before pregnancy. When ritodrine was administered for threatened premature labor at 35 weeks of gestation, her CK level was elevated to over 3900 IU/L. She delivered a full‐term baby via cesarean section but suffered from muscle weakness with elevated CK levels soon after delivery. It has been reported that an unaffected placenta and fetus can improve maternal β‐oxidation during pregnancy. However, in our case, the baby was also affected by VLCAD deficiency. These suggest that the clinical symptoms of a woman with VLCAD deficiency might be reduced during pregnancy even if the fetus is affected with VLCAD deficiency. John Wiley & Sons, Inc. 2019-07-17 /pmc/articles/PMC6718132/ /pubmed/31497477 http://dx.doi.org/10.1002/jmd2.12061 Text en © 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Yamada, Kenji
Matsubara, Keiichi
Matsubara, Yuko
Watanabe, Asami
Kawakami, Sanae
Ochi, Fumihiro
Kuwabara, Kozue
Mushimoto, Yuichi
Kobayashi, Hironori
Hasegawa, Yuki
Fukuda, Seiji
Yamaguchi, Seiji
Taketani, Takeshi
Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title_full Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title_fullStr Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title_full_unstemmed Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title_short Clinical course in a patient with myopathic VLCAD deficiency during pregnancy with an affected baby
title_sort clinical course in a patient with myopathic vlcad deficiency during pregnancy with an affected baby
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718132/
https://www.ncbi.nlm.nih.gov/pubmed/31497477
http://dx.doi.org/10.1002/jmd2.12061
work_keys_str_mv AT yamadakenji clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT matsubarakeiichi clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT matsubarayuko clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT watanabeasami clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT kawakamisanae clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT ochifumihiro clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT kuwabarakozue clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT mushimotoyuichi clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT kobayashihironori clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT hasegawayuki clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT fukudaseiji clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT yamaguchiseiji clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby
AT taketanitakeshi clinicalcourseinapatientwithmyopathicvlcaddeficiencyduringpregnancywithanaffectedbaby